Stocks · News reference
Spruce Biosciences Says It Completed Two Pre-BLA Meetings With FDA Supporting Q4 2026 BLA Submission For Tralesinidase Alfa In Sanfilippo Syndrome Type B; FDA Found CMC Comparability Strategies Reasonable
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Lake Street Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $149
Lake Street analyst Daniel Brims initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $149.
Spruce Biosciences Launches MPS3BStudy.com, Online Resource For Families And Caregivers Of Children With Sanfilippo Syndrome Type B
Website Enables Families and Caregivers of Children with MPS IIIB to Learn About and Register Interest in the TA-ERT Expanded Access Program (EAP) and TrAnsform Confirmatory StudyTA-ERT EAP and TrAnsform Confirmatory